Hanmi Pharmaceutical Group said on the 16th it will expand cash dividends to enhance shareholder value, backed by record-high results last year at the holding company and other key affiliates.
The cash dividend amounts are as follows: ▲ Hanmi Science common stock, 300 won per share (dividend yield 0.79%) ▲ Hanmi Pharmaceutical common stock, 2,000 won per share (dividend yield 0.40%) ▲ JVM common stock, 650 won per share (dividend yield 2.5%).
The cash dividend plan is set to be executed after final approval, with related items to be submitted at each company's regular shareholder meeting on the 31st.
The company said this faithfully carries out the shareholder-return policy officially released at the "Hanmi Vision Day" corporate presentation in December.
Accordingly, it plans to return a set portion of net profit to shareholders. Hanmi Science is targeting a total shareholder return ratio of at least 30%, while Hanmi Pharmaceutical and JVM are each targeting at least 20%.
Hanmi Group unveiled a new vision aiming to reach a combined 5 trillion won in affiliate revenue by 2030, based on a stable management environment. The main strategy is to grow around four core areas: obesity, anti-aging, Digital Healthcare, and Robotics.
Kim Jae-kyo, CEO of Hanmi Science, said, "We are working to maximize the group's future business development and strategic growth opportunities to raise corporate value, while also actively enhancing shareholder value through financial and nonfinancial measures."
Kim said, "We will continue to expand shareholder-friendly policies by maintaining a balance between growth investments and shareholder returns, based on a stable financial structure."
Hanmi Science plans to drive growth of group affiliates and expand high value-added businesses in medical devices and beauty care, with a goal of achieving an operating margin of at least 25% by 2030.
Hanmi Pharmaceutical presented a goal of achieving an operating margin of at least 20% through successful technology transfer based on global R&D capabilities and the launch of blockbuster new drugs at home and abroad, while JVM aims for an operating margin of at least 20% by expanding overseas sales in North America and Europe and broadening its software business.